Drug Used to Combat Opioid Addiction is Being Underprescribed

Drug Used to Combat Opioid Addiction is Being Underprescribed
Author Information (click to view)

American Psychological Association


American Psychological Association (click to view)

American Psychological Association

Advertisement
Access to counseling for patients, mentoring for physicians could help increase use, survey says.
Share on FacebookTweet about this on TwitterShare on LinkedIn

A drug approved for private physicians to treat opioid addiction is being underprescribed, and a survey of addiction specialists suggests that many of them are not willing to increase their use of it, despite an expanding opioid addiction epidemic in the United States, according to research presented at the 125th Annual Convention of the American Psychological Association.

Two opioid replacement medications are currently approved for opioid use disorder: methadone, which under federal law must be dispensed from authorized clinics, and buprenorphine, which can be used to treat opioid addiction in the privacy of a physician’s office, so long as the physician has the proper waivers.

“Though it was widely believed that allowing physicians to prescribe this drug in a primary care setting would increase the number of patients receiving treatment, the number of physicians adopting this therapy has not kept pace with the magnitude of the opioid epidemic,” said Andrew Huhn, PhD, of the Johns Hopkins University School of Medicine.

Buprenorphine was approved for the treatment of opioid use disorder in 2002 with the requirement that physicians apply for a waiver from the Substance Abuse and Mental Health Services Administration in order to prescribe the drug in primary care settings. Its mechanism of action is similar to methadone’s but not quite as intense, hence it is less likely to be abused, but it still adequately suppresses withdrawal symptoms with daily doses. Physicians with waivers are allowed to treat up to 30 patients in the first year and 275 patients in each subsequent year.


Related Articles


Huhn and his colleagues surveyed 558 English-speaking physicians in the United States via email during the spring and summer of 2016. Participants were asked about perceived drawbacks associated with prescribing buprenorphine as well as possible resources that might encourage those who did not have the waiver to obtain it and those who did have the waiver to accept more new patients.

Only 74 respondents indicated they did not have waivers to prescribe the drug. Of those, approximately one-third said that nothing would increase their willingness to get a waiver. The most common reasons for not obtaining a waiver included not wanting to be inundated with patient requests for buprenorphine (29.7 percent) and concerns about patients reselling their medication (25.7 percent).

Click here to read the full press release.

Submit a Comment

Your email address will not be published. Required fields are marked *

13 − 6 =